NEWSPAPER PUBLICATION OF FINANCIAL RESULTS FOR Q.E. AND YEAR ENDED 31ST MARCH 2025
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals Ltd has filed with BSE copies of the newspaper publication of its audited standalone and consolidated financial results for Q4 FY25 and the full year ended March 31, 2025, as required under SEBI's Listing Regulations. The results were published in Financial Express (English) and Punjabi Jagran (Punjabi) on May 21, 2025. On a consolidated basis, total income from operations rose to about Rs. 37,019.70 lakhs in FY25 from roughly Rs. 30,778 lakhs in FY24, while net profit before tax increased to Rs. 5,413.99 lakhs from Rs. 3,819.82 lakhs. For Q4 FY25 alone, consolidated revenue jumped to Rs. 11,567.64 lakhs versus Rs. 8,197.73 lakhs in Q4 FY24, with profit before tax at Rs. 1,907.46 lakhs versus Rs. 1,308.41 lakhs a year earlier. The statutory auditors (M/s Ram Rattan & Associates) issued an unmodified opinion on the financial results.
This is a routine regulatory compliance filing (newspaper publication of already-submitted results), so it is unlikely to move the stock sharply on its own. The strong YoY growth in revenue and profits for both the quarter and full year may provide a mildly positive backdrop, but investors should look to the detailed annual report for the full picture.